Ophthotech adds Dr Cal Roberts to its Board of Directors

– USA, NY –  Ophthotech Corporation (NASDAQ:OPHT) announced today the election of Calvin (Cal) W. Roberts, M.D., Senior Vice President and Chief Medical Officer, Eye Care at Bausch Health Companies and Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, to its Board of Directors, effective as of January 1. Dr. Roberts brings over 25 years of experience in the pharma/biotech industry and is well-respected for his business expertise, industry experience and ophthalmic leadership.

“We are excited to welcome Dr. Roberts, a well-known physician and experienced executive in our industry, to our Board of Directors,” stated Glenn P. Sblendorio, Chief Executive Officer and President of Ophthotech and David R. Guyer, M.D., Executive Chairman of Ophthotech.

Mr. Sblendorio added, “The magnitude of relevant ophthalmic expertise and industry experience that Cal brings to Ophthotech is extremely valuable as we continue to develop and advance our pipeline of novel therapeutics and gene therapies for retinal diseases. We believe the addition of Cal to our Board is another important step as we focus on creating value for shareholders.”

About Dr Cal Roberts

Calvin W. Roberts, M.D. is a renowned specialist in cataract and refractive surgery. Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens. Dr. Roberts is a Senior Vice President and the Chief Medical Officer, Eye Care at Bausch Health Companies. Since 1982, Dr. Roberts has served as a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University. Dr. Roberts previously served as a consultant to Allergan, Inc., Johnson & Johnson and Novartis. Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and was a pioneer in the use of ophthalmic non-steroidals. Dr. Roberts received an A.B. from Princeton University and his M.D. from the College of Physicians and Surgeons of Columbia University. Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital. Dr. Roberts also completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston. Dr. Roberts currently serves as an Independent Director on multiple corporate boards.

“As Ophthotech positions itself at the forefront of developing transformative treatments for orphan and age-related retinal diseases, I am excited to join the Board of Ophthotech at this important time,” stated Dr. Roberts. “Forming partnerships between industry and physicians is extremely important to me, and I look forward to working closely with the Board and management team to build on the foundation that Ophthotech has created.”

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases.

For more, visit www.ophthotech.com.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.